190 related articles for article (PubMed ID: 21149915)
1. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy.
Kitamura S; Tsuge M; Hatakeyama T; Abe H; Imamura M; Mori N; Saneto H; Kawaoka T; Mitsui F; Hiraga N; Takaki S; Kawakami Y; Aikata H; Takahashi S; Ohishi W; Ochi H; Hayes CN; Chayama K
Antivir Ther; 2010; 15(8):1087-97. PubMed ID: 21149915
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
Mori N; Imamura M; Kawakami Y; Saneto H; Kawaoka T; Takaki S; Aikata H; Takahashi S; Chayama K;
J Med Virol; 2009 Apr; 81(4):640-9. PubMed ID: 19235866
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.
Hayashi K; Katano Y; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
J Viral Hepat; 2011 Apr; 18(4):280-6. PubMed ID: 20367792
[TBL] [Abstract][Full Text] [Related]
5. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
[TBL] [Abstract][Full Text] [Related]
6. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.
Yen YH; Hung CH; Hu TH; Chen CH; Wu CM; Wang JH; Lu SN; Lee CM
Aliment Pharmacol Ther; 2008 Jan; 27(1):72-9. PubMed ID: 17973647
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy.
El-Shamy A; Kim SR; Ide YH; Sasase N; Imoto S; Deng L; Shoji I; Hotta H
Intervirology; 2012; 55(1):1-11. PubMed ID: 21293098
[TBL] [Abstract][Full Text] [Related]
9. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.
Okanoue T; Itoh Y; Hashimoto H; Yasui K; Minami M; Takehara T; Tanaka E; Onji M; Toyota J; Chayama K; Yoshioka K; Izumi N; Akuta N; Kumada H
J Gastroenterol; 2009; 44(9):952-63. PubMed ID: 19517057
[TBL] [Abstract][Full Text] [Related]
10. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.
Kurosaki M; Sakamoto N; Iwasaki M; Sakamoto M; Suzuki Y; Hiramatsu N; Sugauchi F; Tamori A; Nakagawa M; Izumi N
J Med Virol; 2011 Mar; 83(3):445-52. PubMed ID: 21264865
[TBL] [Abstract][Full Text] [Related]
11. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.
Nakagawa M; Sakamoto N; Ueyama M; Mogushi K; Nagaie S; Itsui Y; Azuma S; Kakinuma S; Tanaka H; Enomoto N; Watanabe M
J Gastroenterol; 2010 Jun; 45(6):656-65. PubMed ID: 20112032
[TBL] [Abstract][Full Text] [Related]
13. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
Intervirology; 2012; 55(3):231-41. PubMed ID: 21734353
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
[TBL] [Abstract][Full Text] [Related]
15. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C.
Chayama K; Hayes CN; Yoshioka K; Moriwaki H; Okanoue T; Sakisaka S; Takehara T; Oketani M; Toyota J; Izumi N; Hiasa Y; Matsumoto A; Nomura H; Seike M; Ueno Y; Yotsuyanagi H; Kumada H
J Gastroenterol; 2011 Apr; 46(4):545-55. PubMed ID: 21246384
[TBL] [Abstract][Full Text] [Related]
16. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
17. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Matsuda M; Kobayashi M; Arase Y; Ikeda K; Kumada H
Intervirology; 2005; 48(6):372-80. PubMed ID: 16024941
[TBL] [Abstract][Full Text] [Related]
18. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2009 Mar; 81(3):452-8. PubMed ID: 19152407
[TBL] [Abstract][Full Text] [Related]
19. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
Tamai H; Mori Y; Shingaki N; Kawashima A; Tsukuda H; Higashi K; Moribata K; Kawaguchi M; Ueda K; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
Antivir Ther; 2014; 19(1):107-15. PubMed ID: 24162072
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]